Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 11, 2013, Pages 1387-1404

  Dauden E ^a   Castaneda S ^a   Suarez C ^a   Garcia Campayo J ^b   Blasco, A J ^c   Aguilar, M D ^c   Ferrandiz C ^d   Puig, L ^e   Sanchez Carazo J L ^f  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^c Advanced Techniques in Health Services Research (TAISS)   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; CYCLOSPORIN; ETANERCEPT; FOLIC ACID; GOLIMUMAB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; METHOTREXATE; PIOGLITAZONE; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB;

ALCOHOL CONSUMPTION; ANXIETY DISORDER; ARTERIOSCLEROSIS; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL DECISION MAKING; COMORBIDITY; CORONARY ARTERY DISEASE; CROHN DISEASE; DEPRESSION; DERMATOLOGIST; DISEASE SEVERITY; DYSLIPIDEMIA; FOLLOW UP; GASTROINTESTINAL DISEASE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LABORATORY TEST; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; MEDICAL HISTORY; METABOLIC SYNDROME X; MYCOSIS FUNGOIDES; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PATIENT COMPLIANCE; PERIPHERAL VASCULAR DISEASE; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SIDE EFFECT; SMOKING; SYSTEMATIC REVIEW (TOPIC); TOBACCO; TRIACYLGLYCEROL BLOOD LEVEL; ULCERATIVE COLITIS;

COMORBIDITY; HUMANS; PRACTICE GUIDELINES AS TOPIC; PSORIASIS;

EID: 84885961063     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12024     Document Type: Article

References (183)

1. Griffiths CEM, Barrer JNWN,. Psoriasis: pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-271.
2. Christophers E, Barker J, Griffiths C, et al. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol 2010; 24: 548-554.
3. Radtke MA, Reich K, Blome C, et al. Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol 2009; 23: 683-691.
4. Reich K, Kruger K, Mossner R, et al. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 2009; 160: 1040-1047.
5. Nograles KE, Brasington RD, Bowcock AM,. New insights into the pathogenesis and genetics of psoriatic arthritis. Nat Clin Pract Rheumatol 2009; 5: 83-91.
6. Henseler T, Christophers E,. Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32: 982-986.
7. Popa C, Netea MG, Radstake T, et al. Influence of anti tumor necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2005; 64: 303-305.
8. Weyand CM, Goronzy JJ, Liuzzo G, et al. T-cell immunity in acute coronary syndromes. Mayo Clin Proc 2001; 76: 1011-1020.
9. Kao AH, Sabatine JM, Manzi S,. Update on vascular disease in systemic lupus erythematosus. Curr Opin Rheumatol 2003; 15: 519-527.
10. Haslam DW, James WP,. Obesity. Lancet 2005; 366: 1197-1209.
11. Campalni E, Allen MH, Fairhurst D, et al. Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol 2006; 154: 345-352.
12. Eichner JE, Dunn ST, Perveen G, et al. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiolo 2002; 155: 487-495.
13. Chiturri S, Farrell CG,. Etiopathogenesis of nonalcoolic steatohepatitis. Semin Liver Dis 2001; 21: 27-41.
14. Marchesini G, Bugieanesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 36: 917-923.
15. Kotronen A, Yki-Järvinen H,. Fatty liver: a novel component of the metbolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 27-38.
16. Gisondi P, Targher G, Zoppini G, Girolomoni G,. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 758-764.
17. Miele L, Vallone S, Cefalo C, et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 778-786.
18. Capon F, Di Meglio P, Szaub J, et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 2007; 122: 201-206.
19. Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007; 80: 273-290.
20. Nair RP, Ruether A, Stuart PE, et al. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol 2008; 128: 1653-1661.
21. Smith RL, Warren RB, Eyre S, et al. Polymorphisms in the IL-12beta and IL-23R genes are associated with psoriasis of early onset in a UK cohort. J Invest Dermatol 2008; 128: 1325-1327.
22. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314: 1461-1463.
23. Taylor KD, Targan SR, Mei L, et al. IL23R haplotypes provide a large population attributable risk for Crohn's disease. Inflamm Bowel Dis 2008; 14: 1185-1191.
24. Einarsdottir E, Koskinen LL, Dukes E, et al. IL23R in the Swedish, Finnish, Hungarian and Italian populations: association with IBD and psoriasis, and linkage to celiac disease. BMC Med Genet 2009; 10: 8.
25. Gottlieb AB, Dann F,. Comorbidities in patients with psoriasis. Am J Med 2009; 122: 1150-1159.
26. Krueger JG, Bowcock A,. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005; 64 (Suppl. 2): ii30-ii36.
27. Muller KM, Rocken M, Joel D, et al. Mononuclear cell-bound CD23 is elevated in both atopic dermatitis and psoriasis. J Dermatol Sci 1991; 2: 125-133.
28. Jeffes EW, Lee GC, Said S, et al. Elevated numbers of proliferating mononuclear cells in the peripheral blood of psoriatic patients correlate with disease severity. J Invest Dermatol 1995; 105: 733-738.
29. Mahmoud F, Abul H, al Saleh Q, et al. Elevated B-lymphocyte levels in lesional tissue of non-arthritic psoriasis. J Dermatol 1999; 26: 428-433.
30. Koo JY, Kadonaga JN, Wintroub BV, Lozada-Nur FI,. The development of B-cell lymphoma in a patient with psoriasis treated with cyclosporine. J Am Acad Dermatol 1992; 26: 836-840.
31. Kamel OW, Weiss LM, van de Rijn M, et al. Hodgkin's disease and lymphoproliferations resembling Hodgkin's disease in patients receiving long-term low-dose methotrexate therapy. Am J Surg Pathol 1996; 20: 1279-1287.
32. Kamel OW,. Lymphomas during long-term methotrexate therapy. Arch Dermatol 1997; 133: 903-904.
33. Cliff S, Pettengell R, Gharge S, Marsden RA,. B-cell lymphoma developing in a patient on cyclosporin for recalcitrant psoriasis. Br J Dermatol 1999; 140: 763-765.
34. Mahe E, Descamps V, Grossin M, et al. CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br J Dermatol 2003; 149: 170-173.
35. Lelievre JD, Sacre K, Adle-Biassette H, et al. Epstein-Barr virus-associated lymphoproliferative disease after long-standing cyclosporine therapy for psoriasis: a case of spontaneous regression. J Am Acad Dermatol 2005; 52: 24-27.
36. Adler UC, Marques AH, Calil HM,. Inflammatory aspects of depression. Inflamm Allergy Drugs Targets 2008; 7: 19-23.
37. Simen BB, Duman CH, Simen AA, Duman RS,. TNF alpha signaling in depression and anxiety: behavioral consequences of individual receptor targeting. Biol Psychiatry 2006; 59: 775-785.
38. Schiepers OJ, Wichers MC, Maes M,. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 201-217.
39. Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005; 6: 383-392.
40. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125: 61-67.
41. Favato G,. High incidence of smoking habit in psoriatic patients. Am J Med 2008; 121: e17.
42. Zhang X, Wang H, Te-Shao H, et al. Frequent use of tobacco and alcohol in Chinese psoriasis patients. Int J Dermatol 2002; 41: 659-662.
43. Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298: 321-328.
44. Orosz Z, Csiszar A, Labinskyy N, et al. Cigarette smoke-induced proinflammatory alterations in the endotelial phenotype: role of NAD(P)H oxidase activation. Am J Physiol Heart Circ Physiol 2007; 292: H130-H139.
45. Aicher A, Heeschen C, Mophaut M, et al. Nicotine strongly activates dendritic cell-mediated adaptive immunity: potential role for progression of atherosclerotic lesions. Circulation 2003; 1007: e9007.
46. Backer RC, Jerrells TR,. Recent developments in alcoholism: immunological aspects. Recent Dev Alcohol 1993; 11: 249-271.
47. Frohm M, Agerberth B, Ahangari G, et al. The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J Biol Chem 1997; 272: 15258-15263.
48. Ockenfels HM, Nussbaum G, Schneck B, et al. The effect of cyclosporine A and FK 506 on the cAMP content in psoriatic keratinocytes. Skin Pharmacol 1996; 9: 281-288.
49. Wollina U, Hoffmann A, Prochanau D, et al. Keratinocyte growth inhibition by streptococcal proteins. Int J Mol Med 1998; 1: 761-765.
50. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50: 2264-2272.
51. Petersen S, Peto V, Rayner M, et al. European Cardiovascular Disease Statistics: 2005 edition. British Heart Foundation, London, 2005.
52. Dauden E, Castañeda S, Suárez C, et al. Integrated approach to comorbidity in patients with psoriasis. Actas Dermosifiliogr 2012; 103 (Suppl. 1): 1-64.
53. Peloso PM, Behl M, Hull P, Reeder B,. The psoriasis and arthritis questionnaire (PAQ) in detection of arthritis among patients with psoriasis. Arthritis Rheum 1997; 40 (Suppl. 9): S64.
54. Gladman DD, Schentag CT, Tom BD, et al. Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto psoriatic arthritis screen (TOPAS). Ann Rheum Dis 2009; 68: 497-501.
55. Husni ME, Meyer KH, Cohen DS, et al. The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol 2007; 57: 581-587.
56. Ibrahim GH, Buch MH, Lawson C, et al. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis epidemiology screening tool (PEST) questionnaire. Clin Exp Rheum 2009; 27: 469-474.
57. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-2673.
58. Torre JC,. [Utility and application in clinical practice of the CASPAR criteria]. Reumatol Clin 2010; 6 (Suppl. 1): 18-21.
59. Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010; 31: 1000-1006.
60. Xiao J, Chen LH, Tu YT, et al. Prevalence of myocardial infarction in patients with psoriasis in central China. J Eur Acad Dermatol Venereol 2009; 23: 1311-1315.
61. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-1741.
62. Prodanovich S, Kirsner RS, Kravetz JD, et al. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 2009; 145: 700-703.
63. Wakkee M, Herings RM, Nijsten T,. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J Invest Dermatol 2010; 130: 962-967.
64. Brauchli YB, Jick SS, Miret M, Meier CR,. Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis. Br J Dermatol 2009; 160: 1048-1056.
65. Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol. 2009; 129: 2411-2418.
66. Ludwig RJ, Herzog C, Rostock A, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007; 156: 271-276.
67. Mallbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19: 225-230.
68. Van Voorhees AS, Fried R,. Depression and quality of life in psoriasis. Postgrad Med 2009; 121: 154-161.
69. Russo PAJ, Ilchef R, Cooper A,. Psychiatric morbidity in psoriasis: a review. Australas J Dermatol 2004; 45: 155-160.
70. Renzi C, Picardi A, Abeni D, et al. Association of dissatisfaction with care and psychiatric morbidity with poor treatment compliance. Arch Dermatol 2002; 138: 337-342.
71. Bo K, Thoresen M, Dalgard F,. Smokers report more psoriasis, but not atopic dermatitis or hand eczema: results from a Norwegian population survey among adults. Dermatology 2008; 216: 40-45.
72. Naldi L, Peli L, Parazzini F,. Association of early-stage psoriasis with smoking and male alcohol consumption: evidence from an Italian case-control study. Arch Dermatol 1999; 135: 1479-1484.
73. Al-Mutairi N, Al-Farag S, Al-Mutairi A, Al-Shiltawy M,. Comorbidities associated with psoriasis: an experience from the Middle East. J Dermatol 2010; 37: 146-155.
74. Malerba M, Gisondi P, Radaeli A, et al. Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. Br J Dermatol 2006; 155: 1165-1169.
75. Vanizor KB, Orem A, Cimsit G, et al. Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients. Clin Chim Acta 2003; 332: 23-30.
76. Feig DI, Kang D-H, Johnson RJ,. Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811-1821.
77. Martí-Carvajal AJ, Solà I, Lathyris D, Salanti G,. Homocysteine lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 2009; 4: CD006612.
78. Ibrahim G, Waxman R, Helliwell PS,. The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum 2009; 61: 1373-1378.
79. Wilson FC, Icen M, Crowson CS, et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum 2009; 61: 233-239.
80. Ejaz A, Iftikhar A, Iftikhar N,. Patterns of psoriatic arthritis. J Coll Physicians Surg Pak 2009; 19: 553-556.
81. Wu Y, Mills D, Bala M,. Psoriasis: cardiovascular risk factors and other disease comorbidities. J Drugs Dermatol 2008; 7: 373-377.
82. Jamshidi F, Bouzari N, Seirafi H, et al. The prevalence of psoriatic arthritis in psoriatic patients in Tehran, Iran. Arch Iran Med 2008; 11: 162-165.
83. García-Díez A, Foraster CF, Sebastian FV, et al. What characterizes the severity of psoriasis? Results from an epidemiological study of over 3,300 patients in the Iberian region Dermatology 2008; 216: 137-151.
84. Gisondi P, Girolomoni G, Sampogna F, et al. Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. Eur J Dermatol 2005; 15: 279-283.
85. Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005; 141: 1527-1534.
86. Pavlica L, Peric-Hajzler Z, Jovelic A, et al. Psoriatic arthritis: a retrospective study of 162 patients. Vojnosanit Pregl 2005; 62: 613-620.
87. Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005; 53: 573-577.
88. Alenius GM, Stenberg B, Stenlund H, et al. Inflammatory joint manifestations are prevalent in psoriasis: prevalence study of joint and axial involvement in psoriatic patients, and evaluation of a psoriatic and arthritic questionnaire. J Rheumatol 2002; 29: 2577-2582.
89. Ferrándiz C, Pujol RM, García-Patos V, et al. Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol 2002; 46: 867-873.
90. Zachariae H, Zachariae R, Blomqvist K, et al. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations Data from the Nordic Quality of Life Study. Acta Derm Venereol 2002; 82: 108-113.
91. Shbeeb M, Uramoto KM, Gibson LE, et al. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, EEUU, 1982-1991. J Rheumatol 2000; 27: 1247-1250.
92. Salvarani C, Lo Scocco G, Macchioni P, et al. Prevalence of psoriatic arthritis in Italian psoriatic patients. J Rheumatol 1995; 22: 1499-1503.
93. Barisic-Drusko V, Dobric I, Pasic A, et al. Frequency of psoriatic arthritis in general population and among the psoriatics in Department of Dermatology. Acta Derm Venereol Suppl (Stockh) 1994; 186: 107-108.
94. Falk ES, Vandbakk O,. Prevalence of psoriasis in a Norwegian Lapp population. Acta Derm Venereol Suppl (Stockh) 1993; 182: 6-9.
95. Zanolli MD, Wikle JS,. Joint complaints in psoriasis patients. Int J Dermatol 1992; 31: 488-491.
96. Biondi C, Scarpa R, Pucino A, Oriente P,. Psoriasis and psoriatic arthritis. Dermatological and rheumatological co-operative clinical report. Acta Derm Venereol Suppl (Stockh) 1989; 146: 69-71.
97. Stern RS,. The epidemiology of joint complaints in patients with psoriasis. J Rheumatol 1985; 12: 315-320.
98. Driessen RJ, Boezeman JB, van de Kerkhof PC, De Jong EM,. Cardiovascular risk factors in high-need psoriasis patients and its implications for biological therapies. J Dermatolog Treat 2009; 20: 42-47.
99. Kaye JA, Li L, Jick SS,. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008; 159: 895-902.
100. Kimball AB, Robinson D Jr, Wu Y, et al. Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002. Dermatology 2008; 217: 27-37.
101. Shapiro J, Cohen AD, David M, et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 2007; 56: 629-634.
102. Pearce DJ, Morrison AE, Higgins KB, et al. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatolog Treat 2005; 16: 319-323.
103. Augustin M, Reich K, Glaeske G, et al.,. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol 2010; 90: 147-151.
104. Augustin M, Glaeske G, Radtke MA, et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010; 162: 633-636.
105. Bardazzi F, Balestri R, Baldi E, et al. Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy. Dermatol Ther 2010; 23 (Suppl. 1): S14-S19.
106. Huang YH, Yang LC, Hui RY, et al. Relationships between obesity and the clinical severity of psoriasis in Taiwan. J Eur Acad Dermatol Venereol 2010; 24: 1035-1039.
107. Wolk K, Mallbris L, Larsson P, et al. Excessive body weight and smoking associates with a high risk of onset of plaque psoriasis. Acta Derm Venereol 2009; 89: 492-497.
108. Cohen AD, Sherf M, Vidavsky L, et al. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008; 216: 152-155.
109. Naldi L, Chatenoud L, Belloni A, et al. Medical history, drug exposure and the risk of psoriasis. Evidence from an Italian case-control study. Dermatology 2008; 216: 125-130.
110. Huerta C, Rivero E, Rodríguez LA,. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007; 143: 1559-1565.
111. Cohen AD, Gilutz H, Henkin Y, et al. Psoriasis and the metabolic syndrome. Acta Derm Venereol 2007; 87: 506-509.
112. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73.
113. Setty AR, Curhan G, Choi HK,. Obesity, waist circumference, weight change, and the risk of psoriasis in women: nurses' health study II. Arch Intern Med 2007; 167: 1670-1675.
114. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-835.
115. McGowan JW, Pearce DJ, Chen J, et al. The skinny on psoriasis and obesity. Arch Dermatol 2005; 141: 1601-1602.
116. Marino MG, Carboni I, de Felice C, et al. Risk factors for psoriasis: a retrospective study on 501 outpatients clinical records. Ann Ig 2004; 16: 753-758.
117. Qureshi AA, Choi HK, Setty AR, Curhan GC,. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol 2009; 145: 379-382.
118. Brauchli YB, Jick SS, Meier CR,. Psoriasis and the risk of incident diabetes mellitus: a population-based study. Br J Dermatol 2008; 159: 1331-1337.
119. Gerdes S, Zahl VA, Knopf H, et al. Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis. Br J Dermatol 2008; 159: 1116-1123.
120. Cohen AD, Dreiher J, Shapiro Y, et al. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol 2008; 22: 585-589.
121. Cohen AD, Weitzman D, Dreiher J,. Psoriasis and hypertension: a case-control study. Acta Derm Venereol 2010; 90: 23-26.
122. Bajaj DR, Mahesar SM, Devrajani BR, Iqbal MP,. Lipid profile in patients with psoriasis presenting at Liaquat University Hospital Hyderabad. J Pak Med Assoc 2009; 59: 512-515.
123. Akhyani M, Ehsani AH, Robati RM, Robati AM,. The lipid profile in psoriasis: a controlled study. J Eur Acad Dermatol Venereol 2007; 21: 1330-1332.
124. Tekin NS, Tekin IO, Barut F, Sipahi EY,. Accumulation of oxidized low- density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators of Inflamm 2007; 2007: 78454.
125. Farshchian M, Zamanian A, Farshchian M, et al. Serum lipid level in Iranian patients with psoriasis. J Eur Acad Dermatol Venereol 2007; 21: 802-805.
126. Reynoso-von DC, Martínez-Abundis E, Balcazar-Muñoz BR, et al. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. J Am Acad Dermatol 2003; 48: 882-885.
127. Piskin S, Gurkok F, Ekuklu G, Senol M,. Serum lipid levels in psoriasis. Yonsei Med J 2003; 44: 24-26.
128. Raychaudhuri SK, Chatterjee S, Nguyen C, et al. Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord 2010; 8: 331-334.
129. Arias S, Ruiz JC, Girõn MS, et al. [Prevalence of metabolic syndrome in patients with severe psoriasis]. Actual Med 2009; 94: 12-17.
130. Cohen AD, Dreiher J, Birkenfeld S,. Psoriasis associated with ulcerative colitis and Crohn's disease. J Eur Acad Dermatol Venereol 2009; 23: 561-565.
131. Makredes M, Robinson D Jr, Bala M, Kimball AB,. The burden of autoimmune disease: a comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis. J Am Acad Dermatol 2009; 61: 405-410.
132. Ji J, Shu X, Sundquist K, et al. Cancer risk in hospitalised psoriasis patients: a follow-up study in Sweden. Br J Cancer 2009; 100: 1499-1502.
133. Gelfand JM, Shin DB, Neimann AL, et al. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006; 126: 2194-2201.
134. Gelfand JM, Berlin J, Van VA, Margolis DJ,. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003; 139: 1425-1429.
135. Boffetta P, Gridley G, Lindelof B,. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 2001; 117: 1531-1537.
136. Margolis D, Bilker W, Hennessy S, et al. The risk of malignancy associated with psoriasis. Arch Dermatol 2001; 137: 778-783.
137. Hannuksela-Svahn A, Pukkala E, Laara E, et al. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 2000; 114: 587-590.
138. Frentz G, Olsen JH,. Malignant tumours and psoriasis: a follow-up study. Br J Dermatol 1999; 140: 237-242.
139. Kirby B, Richards HL, Mason DL, et al. Alcohol consumption and psychological distress in patients with psoriasis. Br J Dermatol 2008; 158: 138-140.
140. Zachariae R, Zachariae CO, Lei U, Pedersen AF,. Affective and sensory dimensions of pruritus severity: associations with psychological symptoms and quality of life in psoriasis patients. Acta Derm Venereol 2008; 88: 121-127.
141. Schmitt JM, Ford DE,. Role of depression in quality of life for patients with psoriasis. Dermatology 2007; 215: 17-27.
142. Esposito M, Saraceno R, Giunta A, et al. An Italian study on psoriasis and depression. Dermatology 2006; 212: 123-127.
143. Schneider G, Hockmann J, Stander S, et al. Psychological factors in prurigo nodularis in comparison with psoriasis vulgaris: results of a case-control study. Br J Dermatol 2006; 154: 61-66.
144. Yang Y, Koh D, Khoo L, et al. The psoriasis disability index in Chinese patients: contribution of clinical and psychological variables. Int J Dermatol 2005; 44: 925-929.
145. Akay A, Pekcanlar A, Bozdag KE, et al. Assessment of depression in subjects with psoriasis vulgaris and lichen planus. J Eur Acad Dermatol Venereol 2002; 16: 347-352.
146. Richards HL, Fortune DG, Griffiths CE, Main CJ,. The contribution of perceptions of stigmatisation to disability in patients with psoriasis. J Psychosom Res 2001; 50: 11-15.
147. Devrimci-Ozguven H, Kundakci TN, Kumbasar H, Boyvat A,. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J Eur Acad Dermatol Venereol 2000; 14: 267-271.
148. Scharloo M, Kaptein AA, Weinman J, et al. Patients' illness perceptions and coping as predictors of functional status in psoriasis: a 1-year follow-up. Br J Dermatol 2000; 142: 899-907.
149. Jin Y, Yang S, Zhang F, et al. Combined effects of HLA-Cw6 and cigarette smoking in psoriasis vulgaris: a hospital-based case-control study in China. J Eur Acad Dermatol Venereol 2009; 23: 132-137.
150. Fortes C, Mastroeni S, Leffondre K, et al. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol 2005; 141: 1580-1584.
151. World Health Organisation (WHO). Obesity: Preventing and Managing the Global Epidemic. Report on a WHO Consultation. WHO, Geneva, 2000. WHO technical report series 894.
152. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005; 112: 2735-2752.
153. American Diabetes Association. Clinical practice recommendations 2011. Diabetes Care 2011; 34: S1-S2; doi:10.2337/dc11-S001.
154. Mancia G, de Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-1536.
155. Grundy SM, Cleeman JI, Bairey Merz CN, et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004; 110: 227-239.
156. Goldberg D, Bridges K, Duncan-Jones P, et al. Detecting anxiety and depression in general medical settings. BMJ 1988; 297: 897-899.
157. Robledo T, Ortega R, Cabezas C, et al. [Recommendations for lifestyle]. Aten Primaria 2003; 32 (Suppl. 2): 30-44.
158. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373: 633-640.
159. Kavanaugh A, Menter A, Mendelsohn A, et al. Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial. Curr Med Res Opin 2010; 26: 2385-2392.
160. Fernández-Sueiro JL, Juanola-Roura X, Cañete-Crespillo J, et al. [Consensus Document SER on the use of biological therapies in psoriatic arthritis]. Reumatol Clin 2011; 7: 179-188.
161. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009; 60: 976-986.
162. Soriano ER, Rosa J,. Update on the treatment of peripheral arthritis in psoriatic arthritis. Curr Rheumatol Rep 2009; 11: 270-277.
163. Prodanovich S, Ma F, Taylor JR, et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005; 52: 262-267.
164. Jacobsson LT, Turesson C, Gülfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1213-1218.
165. Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007; 6: 2905-2912.
166. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol 2008; 58: 826-850.
167. Saraceno R, Schipani C, Mazzotta A, et al. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res 2008; 57: 290-295.
168. Gisondi P, Cotena C, Tessari G, Girolomoni G,. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 2008; 22: 341-344.
169. Esposito M, Mazzotta A, Saraceno R, et al. Influence and variation of the body mass index in patients treated with etanercept for plaque-type psoriasis. Int J Immunopathol Pharmacol 2009; 22: 219-225.
170. Itoh S, Kanazuka A, Akimoto T,. Combined treatment with ursodeoxycholic acid and pioglitazone in a patient with NASH associated with type 2 diabetes and psoriasis. Dig Dis Sci 2003; 48: 2182-2186.
171. Robertshaw H, Friedman PS,. Pioglitazone: a promising therapy for psoriasis. Br J Dermatol 2005; 152: 189-191.
172. Shafiq N, Malhotra S, Pahndhi P, et al. Pilot trial: pioglitazone versus placebo in patients with plaque psoriasis (the P6). Int J Dermatol 2005; 44: 328-333.
173. Bongartz T, Coras B, Vogt T, et al. Treatment of active psoriatic arthritis with the PPARγ ligand pioglitazone: an open-label pilot study. Rheumatology 2005; 44: 126-129.
174. Canadian Psoriasis Guidelines Committee. Canadian Guidelines for the Management of Plaque Psoriasis. [WWW document] 2009. URL http://www.dermatology. ca/psoriasisguidelines (last accessed: 13 September 2010).
175. Brauchli YB, Jick SS, Curtin F, Meier CR,. Association between beta-blockers, other antihypertensive drugs and psoriasis: population-based case-control study. Br J Dermatol 2008; 158: 1299-1307.
176. Shirinsky IV, Shirinsky VS,. Efficacy of simvastatin in plaque psoriasis: a pilot study. J Am Acad Dermatol 2007; 57: 529-531.
177. Rajpara AN, Goldner R, Gaspari A,. Psoriasis: can statins play a dual role? Dermatol Online J 2010; 16: 2.
178. Alfadhli AAF, McDonald JW, Feagan BG,. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev 2005; 1: CD003459.
179. Patel V, MacDonald JK, McDonald JW, Chande N,. Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009; 4: CD006884.
180. Menter A, Augustin M, Signorovitch J, et al. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol 2010; 62: 812-818.
181. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006; 367: 29-35.
182. Yeung CK, Chan HHL,. Cutaneous adverse effects of lithium: Epidemiology and management. Am J Clin Dermatol 2004; 5: 3-8.
183. Chan HH, Wing Y, Su R, et al. A control study of the cutaneous side effects of chronic lithium therapy. J Affect Disord 2000; 57: 107-113.